Severance package

Discussion in 'Supernus' started by anonymous, Oct 7, 2019 at 12:40 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Thank you for saying this.
     

  2. anonymous

    anonymous Guest

    Also thank you for helping a lonely gay janitor.
     
  3. anonymous

    anonymous Guest

     
  4. anonymous

    anonymous Guest

    We will sell txr too march to 22 or 23 The quacks go generic not us
     
  5. anonymous

    anonymous Guest

    And if you don’t think that will make TXR defunct, than you are just as idiotic as your grammar indicates.
     
  6. anonymous

    anonymous Guest

    You are officially insane
     
  7. anonymous

    anonymous Guest

    Yeah there’s a reason Qxr didn’t take off. It didn’t stand up clinically. A generic of that product is essentially generic IR topiramate that can be dosed once a day “on label.” Dosing convenience aside, it doesn’t offer anywhere close to the same benefits TXR does. We will compete with it the same way we have IR since day 1.
     
  8. anonymous

    anonymous Guest

    We will know pretty soon wont we.
     
  9. anonymous

    anonymous Guest

    Haha or we can be confident and know now that it won’t be a big deal for us. That’s not to say ignore it, as that would be bad business, but from every angle currently(pricing, clinical profile, Rx volume) it doesn’t seem to be a threat.

    I feel bad, I think you might see yourself as a rational realist while thinking those of us on here defending as silly optimists. Just being honest, you come off as a negative pessimist. What we defend with is real facts. What you try to ignite fear with is speculation...
     
  10. anonymous

    anonymous Guest

    Real facts...… Has the generic AG released their pricing yet?? If so I guess I missed that. What about their formulary?? Do you really think we are going to be able to attain any new TXR script without having to Step Through the AG Generic??? You my friend are not an optimist you are completely oblivious. Now stop trying to interview for an RD role on Cafepharma.

    Lets reconnect in March next year to see if there pricing and access is any different than TXR.
     
  11. anonymous

    anonymous Guest

    I really don’t want to be mean to you, but the fact that you’ve said “AG Generic” and “generic AG” let’s me know that you don’t understand what you are talking about. AG stands for Authorized Generic. So what you are saying is Authorized Generic Generic or Generic Authorized Generic...

    The AG of QXR has been around since the moment they launched. Didn’t hurt us then, won’t hurt us now. Let’s not forget the fact that clinically that product doesn’t show the same advantages TXR does over IR. Come on man, the idea that you’re smarter than everyone here and only you can see the end of us while everyone else is oblivious is ridiculous. Nobody is against you. If you are here, we want you to do well and believe in what we are trying to do.
     
  12. anonymous

    anonymous Guest

    CLINICALLY? Are you serious????? TXR didn’t even have a phase 3 study we have ZERO clinical data outside of bioequivalence. The “data” we masquerade around in front of docs is from a chart pull. Proves NOTHING! Get over yourself. This kind of logic got us into this mess when you guys should have been finding us something new to sell.
     
  13. anonymous

    anonymous Guest

    Just to clear confusion what is coming is not the same thing we have seen over the past few years and you know that. We will know if having a legitimate topiramate er will disrupt our ability to capture share pretty soon. I hope that I am sooooooo wrong and you are right I just don't think you look at things logically anymore. Remember that one time you said patients didn't want to deal with an injection and they were dangerous to the patient?????
     
  14. anonymous

    anonymous Guest

    Never said that. The one thing we agree on is you being wrong. You hope for it, I just know it. You don’t win these fights lol. If you want proof of that think about putting your name to what you’ve said and everyone in the company seeing. I’d be ok with what I’ve said. Would you?
     
  15. anonymous

    anonymous Guest

    Not talking about data. If you haven’t talked to your docs and heard first hand about the real clinical differences between Tpm ER and TXR then I get why you are so bitter. That’s not a dig at your selling abilities, just saying you might want to check in with them about how patients react to each drug.
     
  16. anonymous

    anonymous Guest

    what a joke. The docs says it’s better than qudexy everybody so we are saved. The PK is almost identical. No doc has ever said ones better than the other
     
  17. anonymous

    anonymous Guest

    You’re a joke man. Everyone’s done with you.
     
  18. anonymous

    anonymous Guest

    I think you are mistaking this poster with TXR which the data from our doctors support they are done with.
     
  19. anonymous

    anonymous Guest

    I will be more than happy to do that if you can agree to give proper updates at POA's. This nonsense of waiting to provide important updates till after the POA just because it is a difficult discussion with the field is nothing short of ridiculous. You really expect us to believe you didn't know about this 877-264-2440 nonsense until after the POA. I'm just following the cowardly example you are setting.
     
  20. anonymous

    anonymous Guest

    what’s with the phone number?